Lexaria Bioscience (LEXX) FCF Margin (2017 - 2026)
Lexaria Bioscience (LEXX) posted FCF Margin of 11023.44% for Q1 2026, down 625.86% sequentially from 1518.68% in Q3 2025, and down 1016258.0% YoY from N/an in Q1 2025.
Lexaria Bioscience (LEXX) FCF Margin (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported FCF Margin for 10 years, with the latest figure at 11023.44% in Q1 2026.
- Quarterly FCF Margin fell 1016258.0% year-over-year to 11023.44% in Q1 2026, while the trailing twelve-month figure through May 2026 was 3848.61% (down 226283.0% YoY) and the FY2025 annual result came in at 1483.88%, down 40650.0% from the prior year.
- FCF Margin declined to 11023.44% in Q1 2026 per LEXX's latest filing, from 1518.68% in the prior quarter.
- Over five years, FCF Margin peaked at 427.32% in Q1 2024 and troughed at 11023.44% in Q1 2026.
- A 5-year average of 2721.32% and a median of 1512.96% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2026: FCF Margin jumped 741306 bps in 2022, then plunged 1016258 bps in 2026.
- Over 5 years, FCF Margin stood at 1295.15% in 2022, then soared by 40 bps to 781.11% in 2023, then plunged by 91 bps to 1495.57% in 2024, then slipped by 2 bps to 1518.68% in 2025, then sank by 626 bps to 11023.44% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 11023.44%, 1518.68%, and 2059.74% for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -11,023.44% |
| Aug 31, 2025 | -1,518.68% |
| May 31, 2025 | -2,059.74% |
| Feb 28, 2025 | -860.86% |
| Nov 30, 2024 | -1,495.57% |
| Aug 31, 2024 | -2,303.18% |
| May 31, 2024 | -1,507.23% |
| Feb 29, 2024 | -427.32% |
| Nov 30, 2023 | -781.11% |
| Aug 31, 2023 | -5,275.30% |
| May 31, 2023 | -2,298.33% |
| Feb 28, 2023 | -6,199.88% |
| Nov 30, 2022 | -1,295.15% |
| Aug 31, 2022 | -1,058.59% |
| May 31, 2022 | -1,269.54% |
| Feb 28, 2022 | -4,167.28% |
| Nov 30, 2021 | -8,708.21% |
| Aug 31, 2021 | -3,585.28% |
| May 31, 2021 | -566.86% |
| Feb 28, 2021 | -332.22% |